To grab the stroma by the horns: From biology to cancer therapy with mesenchymal stem cells

Oncotarget

Volumn 4, Issue 5, 2013, Pages 651-664

  Droujinine, Ilia A ^a   Eckert, Mark A ^b   Zhao, Weian ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell therapy; Mesenchymal stem cells; Microenvironment; Stroma; Tumor associated fibroblasts

Indexed keywords

ARTICLE; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL ENGINEERING; CELL HOMING; CELL INTERACTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CYTOLOGY; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOCOMPETENT CELL; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; METASTASIS; NONHUMAN; PLEIOTROPY; STEM CELL MOBILIZATION; STROMA; TUMOR GROWTH; TUMOR STROMA;

EID: 84880298933     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1040     Document Type: Article

References (82)

1. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer research. 2010;70:5649-69.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
3. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell. 2012;21:309-22.
4. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
5. Da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem cells (Dayton, Ohio). 2008;26:2287-99.
6. Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PloS one. 2012;7:e30563.
7. Zhang Y, Daquinag AC, Amaya-Manzanares F, Sirin O, Tseng C, Kolonin MG. Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. Cancer research. 2012;72:5198-208.
8. Kang SK, Shin IS, Ko MS, Jo JY, Ra JC. Journey of mesenchymal stem cells for homing: strategies to enhance effcacy and safety of stem cell therapy. Stem cells international. 2012;2012:342968.
9. Sipkins DA, Wei X, Wu JW, Runnels JM, Côté D, Means TK, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435:969-73.
10. Raaijmakers MHGP, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464:852-7.
11. Méndez-Ferrer S, Michurina T V, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:829-34.
12. Xishan Z, Guangyu A, Yuguang S, Hongmei Z. The research on the immuno-modulatory defect of mesenchymal stem cell from Chronic Myeloid Leukemia patients. Journal of experimental &clinical cancer research : CR. 2011;30:47.
13. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Molecular therapy : the journal of the American Society of Gene Therapy. 2009;17:183-90.
14. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, Van de Water JAJM, Mohapatra G, et al. Assessment of therapeutic effcacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 2009;106:4822-7.
15. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clinical cancer research : an offcial journal of the American Association for Cancer Research. 2009;15:7246-55.
16. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem cells (Dayton, Ohio). 2009;27:2614-23.
17. Wu Y, Zhao RCH, Tredget EE. Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem cells (Dayton, Ohio). 2010;28:905- 15.
18. Hong HS, Lee J, Lee E, Kwon YS, Lee E, Ahn W, et al. A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nature medicine. 2009;15:425-35.
19. Wang C-H, Cherng W-J, Yang N-I, Kuo L-T, Hsu C-M, Yeh H-I, et al. Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arteriosclerosis, thrombosis, and vascular biology. 2008;28:54-60.
20. He Q, Wan C, Li G. Concise review: multipotent mesenchymal stromal cells in blood. Stem cells (Dayton, Ohio). 2007;25:69-77.
21. Fathke C, Wilson L, Hutter J, Kapoor V, Smith A, Hocking A, et al. Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem cells (Dayton, Ohio). 2004;22:812-22.
22. Ishii G, Sangai T, Oda T, Aoyagi Y, Hasebe T, Kanomata N, et al. Bone-marrow-derived myofbroblasts contribute to the cancer-induced stromal reaction. Biochemical and biophysical research communications. 2003;309:232-40.
23. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, et al. Bone marrow contribution to tumor-associated myofbroblasts and fbroblasts. Cancer research. 2004;64:8492-5.
24. Quante M, Tu SP, Tomita H, Gonda T, Wang SSW, Takashi S, et al. Bone marrow-derived myofbroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer cell. 2011;19:257-72.
25. Worthley DL, Ruszkiewicz A, Davies R, Moore S, Nivison-Smith I, Bik To L, et al. Human gastrointestinal neoplasia-associated myofbroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem cells (Dayton, Ohio). 2009;27:1463-8.
26. Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem cells (Dayton, Ohio). 2010;28:1435-45.
27. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al. Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth. Cell. 2013;153:139-52.
28. Sjöholm I, Edman P. Acrylic microspheres in vivo. I. Distribution and elimination of polyacrylamide microparticles after intravenous and intraperitoneal injection in mouse and rat. The Journal of pharmacology and experimental therapeutics. 1979;211:656-62.
29. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer research. 2002;62:3603-8.
30. Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, et al. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. The journal of gene medicine. 2008;10:1071-82.
31. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer research. 2009;69:8932-40.
32. Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS, et al. Traffcking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem cells (Dayton, Ohio). 2009;27:1548-58.
33. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer research. 2007;67:11687- 95.
34. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. The Journal of experimental medicine. 2006;203:1235-47.
35. Hung S-C, Deng W-P, Yang WK, Liu R-S, Lee C-C, Su T-C, et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clinical cancer research : an offcial journal of the American Association for Cancer Research. 2005;11:7749-56.
36. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Journal of the National Cancer Institute. 2004;96:1593-603.
37. Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem cells (Dayton, Ohio). 2008;26:2332-8.
38. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer research. 2009;69:4134-42.
39. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer research. 2010;70:7042-52.
40. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of infammation: the leukocyte adhesion cascade updated. Nature reviews. Immunology. 2007;7:678-89.
41. Segers VFM, Van Riet I, Andries LJ, Lemmens K, Demolder MJ, De Becker AJML, et al. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. American journal of physiology. Heart and circulatory physiology. 2006;290:H1370-7.
42. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic infammation: a magic bullet? Science (New York, N.Y.). 2013;339:286-91.
43. Beckermann BM, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J, et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. British journal of cancer. 2008;99:622-31.
44. Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M, et al. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 2010;66:144-56; discussion 156-7.
45. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer research. 2011;71:614-24.
46. Chamberlain G, Smith H, Rainger GE, Middleton J. Mesenchymal stem cells exhibit frm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear. PloS one. 2011;6:e25663.
47. Teo GSL, Ankrum JA, Martinelli R, Boetto SE, Simms K, Sciuto TE, et al. Mesenchymal Stem Cells Transmigrate Between and Directly Through Tumor Necrosis Factor-a-Activated Endothelial Cells Via Both Leukocyte-Like and Novel Mechanisms. Stem cells (Dayton, Ohio). 2012;30:2472-86.
48. Ponte AL, Marais E, Gallay N, Langonné A, Delorme B, Hérault O, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem cells (Dayton, Ohio). 2007;25:1737-45.
49. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem cells (Dayton, Ohio). 2006;24:1030-41.
50. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiology of disease. 2004;16:1-13.
51. Matsushita T, Kibayashi T, Katayama T, Yamashita Y, Suzuki S, Kawamata J, et al. Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neuroscience letters. 2011;502:41-5.
52. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. Karger Publishers; 2001;169:12-20.
53. Furlani D, Ugurlucan M, Ong L, Bieback K, Pittermann E, Westien I, et al. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvascular research. 2009;77:370-6.
54. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary frst-pass effect. Stem cells and development. 2009;18:683- 92.
55. Roodhart JML, Daenen LGM, Stigter ECA, Prins H-J, Gerrits J, Houthuijzen JM, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer cell. 2011;20:370-83.
56. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557-63.
57. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fbroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335-48.
58. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820-7.
59. Mercier FE, Ragu C, Scadden DT. The bone marrow at the crossroads of blood and immunity. Nature reviews. Immunology. 2012;12:49-60.
60. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102:3837-44.
61. Ghannam S, Bouff C, Djouad F, Jorgensen C, Noël D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem cell research &therapy. 2010;1:2.
62. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499-506.
63. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature reviews. Immunology. 2008;8:726-36.
64. Li H-J, Reinhardt F, Herschman HR, Weinberg RA. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer discovery. 2012;2:840-55.
65. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, et al. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. The Journal of clinical investigation. 2011;121:3206-19.
66. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem cells (Dayton, Ohio). 2011;29:11-9.
67. Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noël D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation. 2006;82:1060- 6.
68. Ma M, Ye JY, Deng R, Dee CM, Chan GC-F. Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/CXCR4 and SDF-1/CXCR7 signaling. Cancer letters. 2011;312:1-10.
69. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell stem cell. 2009;4:206-16.
70. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends in molecular medicine. 2010;16:203-9.
71. Bacac M, Stamenkovic I. Metastatic cancer cell. Annual review of pathology. Annual Reviews; 2008;3:221-47.
72. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008;57:1759-67.
73. Langer HF, Stellos K, Steingen C, Froihofer A, Schönberger T, Krämer B, et al. Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro. Journal of molecular and cellular cardiology. 2009;47:315- 25.
74. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. The Journal of cell biology. 2011;192:373- 82.
75. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nature reviews. Cancer. 2002;2:266-76.
76. Rice J. Metastasis: The rude awakening. Nature. 2012;485:S55-7.
77. Zhao W, Schafer S, Choi J, Yamanaka YJ, Lombardi ML, Bose S, et al. Cell-surface sensors for real-time probing of cellular environments. Nature nanotechnology. 2011;6:524- 31.
78. Sarkar D, Vemula PK, Teo GSL, Spelke D, Karnik R, Wee LY, et al. Chemical engineering of mesenchymal stem cells to induce a cell rolling response. Bioconjugate chemistry. 2008;19:2105-9.
79. Sarkar D, Spencer JA, Phillips JA, Zhao W, Schafer S, Spelke DP, et al. Engineered cell homing. Blood. 2011;118:e184-91.
80. Zhao W, Loh W, Droujinine IA, Teo W, Kumar N, Schafer S, et al. Mimicking the infammatory cell adhesion cascade by nucleic acid aptamer programmed cell-cell interactions. FASEB journal : offcial publication of the Federation of American Societies for Experimental Biology. 2011;25:3045-56.
81. Sarkar D, Vemula PK, Zhao W, Gupta A, Karnik R, Karp JM. Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. Biomaterials. 2010;31:5266-74.
82. Uchibori R, Tsukahara T, Mizuguchi H, Saga Y, Urabe M, Mizukami H, et al. NF-κB activity regulates mesenchymal stem cell accumulation at tumor sites. Cancer research. 2012;73:364-72.